[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 34
1. Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD: A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol; 2014 Nov;21(12):3931-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients had a history of colorectal adenocarcinoma hepatic metastases and underwent curative metastasectomy, while three other patients had unresectable stage IV disease.
  • [MeSH-major] Adenocarcinoma / therapy. Cancer Vaccines / therapeutic use. Colorectal Neoplasms / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Macrophage Colony-Stimulating Factor / administration & dosage. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / administration & dosage. Clinical Trials, Phase I as Topic. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Feasibility Studies. Female. Follow-Up Studies. Humans. Immunotherapy. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Safety. Survival Rate. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vaccine. 2005 Mar 18;23(17-18):2379-87 [15755632.001]
  • [Cites] Hum Gene Ther. 1999 Aug 10;10(12):1983-91 [10466632.001]
  • [Cites] Adv Immunol. 2006;90:51-81 [16730261.001]
  • [Cites] Urol Oncol. 2006 Sep-Oct;24(5):419-24 [16962494.001]
  • [Cites] Eur J Immunol. 2006 Nov;36(11):2832-6 [17051620.001]
  • [Cites] Vaccine. 2007 Feb 19;25(9):1607-18 [17166639.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1455-63 [18316569.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5911-8 [19805669.001]
  • [Cites] Clin Transl Sci. 2008 Dec;1(3):228-39 [20357913.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907 [20647400.001]
  • [Cites] N Engl J Med. 2010 Aug 19;363(8):711-23 [20525992.001]
  • [Cites] N Engl J Med. 2010 Jul 29;363(5):411-22 [20818862.001]
  • [Cites] Ann Surg. 2011 Feb;253(2):328-35 [21217520.001]
  • [Cites] BMC Cancer. 2012;12:144 [22494623.001]
  • [Cites] Expert Rev Vaccines. 2012 Jul;11(7):857-68 [22913261.001]
  • [Cites] J Natl Compr Canc Netw. 2013 Feb 1;11(2):141-52; quiz 152 [23411381.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):145-56 [11134207.001]
  • [Cites] Clin Exp Immunol. 2002 Jul;129(1):99-106 [12100028.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):810-20 [12900373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 [8097319.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1537-46 [9108457.001]
  • [Cites] Hum Gene Ther. 1998 Apr 10;9(6):835-43 [9581906.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2309-16 [9815629.001]
  • [Cites] Ann Surg. 2013 Dec;258(6):879-86 [23657083.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1591-602 [15883172.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):459-67 [15905855.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii144-9 [15958446.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):223-9 [15958210.001]
  • [Cites] Cancer Immunol Immunother. 2005 Aug;54(8):750-8 [15614528.001]
  • [Cites] Gastroenterology. 2013 Jun;144(6):1230-40 [23622132.001]
  • [Cites] J Natl Compr Canc Netw. 2013 May 1;11(5):519-28 [23667203.001]
  • [Cites] Expert Rev Vaccines. 2005 Jun;4(3):329-50 [16026248.001]
  • (PMID = 24943235.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA104160; United States / NCI NIH HHS / CA / K23 CA 104160-05; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / K23 CA148964; United States / NCI NIH HHS / CA / R01 CA112160; United States / NCI NIH HHS / CA / R01 CA169702
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Cancer Vaccines; 81627-83-0 / Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS612349; NLM/ PMC4192092
  •  go-up   go-down


2. Leven EA, Maffucci P, Ochs HD, Scholl PR, Buckley RH, Fuleihan RL, Geha RS, Cunningham CK, Bonilla FA, Conley ME, Ferdman RM, Hernandez-Trujillo V, Puck JM, Sullivan K, Secord EA, Ramesh M, Cunningham-Rundles C: Hyper IgM Syndrome: a Report from the USIDNET Registry. J Clin Immunol; 2016 Jul;36(5):490-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data fields included demographics, criteria for diagnosis, pedigree analysis, mutations, clinical features, treatment and transplant records, laboratory findings, and mortality.
  • 78 % experienced non-infectious complications: chronic diarrhea (n = 22), aphthous ulcers (n = 28), and neoplasms (n = 8) including colon cancer, adrenal adenoma, liver adenocarcinoma, pancreatic carcinoid, acute myeloid leukemia, hepatoma, and, in a female with an autosomal dominant gain of function mutation in PIK3CD, an ovarian dysgerminoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 1997 Jul;131(1 Pt 1):47-54 [9255191.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2170-3 [7681587.001]
  • [Cites] Br J Haematol. 2010 Apr;149(2):167-80 [20180797.001]
  • [Cites] Cell. 2000 Sep 1;102(5):565-75 [11007475.001]
  • [Cites] J Allergy Clin Immunol. 2015 Oct;136(4):1018-24 [25840720.001]
  • [Cites] Nat Immunol. 2003 Oct;4(10):1023-8 [12958596.001]
  • [Cites] J Clin Invest. 1999 Apr;103(8):1151-8 [10207167.001]
  • [Cites] Nat Immunol. 2014 Jan;15(1):88-97 [24165795.001]
  • [Cites] J Allergy Clin Immunol. 2014 Jul;134(1):233-6 [24698326.001]
  • [Cites] J Allergy Clin Immunol. 2012 Mar;129(3):778-86 [22154528.001]
  • [Cites] Pediatr Blood Cancer. 2015 Dec;62(12):2216-22 [26291959.001]
  • [Cites] Clin Immunol. 2001 Mar;98(3):313-8 [11237554.001]
  • [Cites] Medicine (Baltimore). 2003 Nov;82(6):373-84 [14663287.001]
  • [Cites] Nat Immunol. 2010 Sep;11(9):836-45 [20676093.001]
  • [Cites] Am J Hum Genet. 2000 Dec;67(6):1555-62 [11047757.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1881-90 [15358621.001]
  • [Cites] J Allergy Clin Immunol. 2003 Nov;112(5):973-80 [14610491.001]
  • [Cites] J Clin Immunol. 2014 May;34(4):428-35 [24711005.001]
  • [Cites] J Clin Immunol. 2014 Apr;34(3):272-6 [24610295.001]
  • [Cites] Pediatr Infect Dis J. 2003 Apr;22(4):329-35 [12690272.001]
  • [Cites] Int Immunol. 1993 Jul;5(7):769-73 [8103673.001]
  • [Cites] J Clin Immunol. 2015 Nov;35(8):696-726 [26482257.001]
  • [Cites] J Clin Immunol. 2014 Feb;34(2):146-56 [24402618.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(12):1215-8 [9894727.001]
  • [Cites] Science. 1993 Feb 12;259(5097):990-3 [7679801.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2421-34 [9746782.001]
  • [Cites] Arthritis Res Ther. 2012 Jul 30;14(4):218 [22894609.001]
  • [Cites] J Clin Invest. 1994 Aug;94(2):616-22 [7518839.001]
  • [Cites] Pediatr Res. 2004 Oct;56(4):519-25 [15319456.001]
  • [Cites] Cell. 1993 Jan 29;72(2):291-300 [7678782.001]
  • [Cites] J Clin Immunol. 2008 May;28 Suppl 1:S62-6 [18246414.001]
  • [Cites] Expert Rev Clin Immunol. 2014 Jan;10(1):91-105 [24308834.001]
  • [Cites] Science. 2013 Nov 15;342(6160):866-71 [24136356.001]
  • [Cites] J Clin Invest. 1995 Mar;95(3):1389-93 [7533792.001]
  • [Cites] Clin Rev Allergy Immunol. 2014 Apr;46(2):120-30 [23797640.001]
  • [Cites] Clin Immunol. 2000 Dec;97(3):203-10 [11112359.001]
  • [Cites] Immunol Rev. 2005 Feb;203:48-66 [15661021.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):977-83 [8993019.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):196-201 [8550833.001]
  • (PMID = 27189378.001).
  • [ISSN] 1573-2592
  • [Journal-full-title] Journal of clinical immunology
  • [ISO-abbreviation] J. Clin. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U24 AI086037; United States / NIAID NIH HHS / AI / P01 AI061093; United States / NIAID NIH HHS / AI / R18 AI048693; United States / NIGMS NIH HHS / GM / T32 GM007280; United States / NIAID NIH HHS / AI / R21 AI101093
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 147205-72-9 / CD40 Ligand
  • [Other-IDs] NLM/ NIHMS792665 [Available on 07/01/17]; NLM/ PMC5039943 [Available on 07/01/17]
  • [Keywords] NOTNLM ; CD40/CD40L / Hyper IgM Syndrome / Primary immune deficiency / USIDNET
  •  go-up   go-down


3. Sfakianaki O, Tzardi M, Voumvouraki A, Afgoustaki A, Koulentaki M, Kouroumalis E: Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis. World J Hepatol; 2013 Oct 27;5(10):568-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of disease specific autoantibodies against liver sinusoidal cells in primary biliary cirrhosis.
  • AIM: To investigate the presence of autoantibodies directed against liver sinusoidal cells in primary biliary cirrhosis (PBC).
  • METHODS: Liver biopsies from 21 PBC patients were studied and compared with 12 liver biopsies from disease controls [3 patients with hepatitis B (HBV) virus, 3 patients with hepatitis C virus (HCV), 3 patients with non-alcoholic steatohepatitis and 3 patients with acute alcoholic hepatitis (AAH)].
  • As healthy controls, we used tissue specimens adjacent to metastatic liver adenocarcinoma.
  • The determination of the cell type targeted by autoantibodies present in the patients sera was performed by indirect immunofluorescence (IIF) analysis using paraffin-embedded liver sections as a substrate.
  • No staining was observed when either normal or PBC sera were used as a primary antibody on liver sections from the disease control group.
  • CONCLUSION: In this study, for the first time in diseased liver tissue, we have demonstrated that a large proportion of PBC patients have disease specific autoantibodies against liver sinusoidal cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24179616.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3812459
  • [Keywords] NOTNLM ; Autoantibodies / Cholangiocytes / Liver tissue / Primary biliary cirrhosis / Sinusoidal cells
  •  go-up   go-down


Advertisement
4. Rostami Nejad M, Aldulaimi D, Ishaq S, Ehsani-Ardakani MJ, Zali MR, Malekzadeh R, Rostami K: Geographic trends and risk of gastrointestinal cancer among patients with celiac disease in Europe and Asian-Pacific region. Gastroenterol Hepatol Bed Bench; 2013;6(4):170-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Celiac disease is an autoimmune disorder that affects genetically predisposed individuals upon the ingestion of gluten.
  • Celiac disease predisposes to the development of gastrointestinal malignancies, especially lymphomas and small bowel adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24834268.001).
  • [ISSN] 2008-2258
  • [Journal-full-title] Gastroenterology and hepatology from bed to bench
  • [ISO-abbreviation] Gastroenterol Hepatol Bed Bench
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC4017519
  • [Keywords] NOTNLM ; Adenocarcinoma / Asian Pacific region / Celiac disease / Europe / Lymphoma
  •  go-up   go-down


5. Li J, Chen XL, Shaker A, Oshima T, Shan J, Miwa H, Feng C, Zhang J: Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponectin. Ann N Y Acad Sci; 2016 Sep;1380(1):183-194
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastroesophageal reflux disease (GERD) has become the most commonly seen gastrointestinal disorder in outpatient clinics.
  • Although clinical complaints can be mild or moderate, patients with GERD may develop further complications, such as peptic strictures, Barrett's esophagus (BE), and even esophageal adenocarcinoma.

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 New York Academy of Sciences.
  • [Cites] Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51 [26526079.001]
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 1):C1-9 [10409103.001]
  • [Cites] J Cell Biol. 2002 Mar 18;156(6):1099-111 [11889141.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):34-41; quiz 311 [17631128.001]
  • [Cites] Diabetes Obes Metab. 2006 May;8(3):264-80 [16634986.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2412-21 [17570215.001]
  • [Cites] Dig Dis Sci. 2008 Mar;53(3):597-605 [17763959.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):1084-9 [11798186.001]
  • [Cites] Lab Invest. 2012 Jan;92(1):22-31 [21912379.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 16;95(14):1053-61 [12865451.001]
  • [Cites] Clin Gastroenterol Hepatol. 2015 Dec;13(13):2256-64.e1-3 [25632808.001]
  • [Cites] J Toxicol Sci. 2012;37(3):491-501 [22687989.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1119-29 [11470739.001]
  • [Cites] Biochem Biophys Res Commun. 2012 Aug 31;425(3):560-4 [22925674.001]
  • [Cites] Cell Rep. 2014 May 22;7(4):1197-210 [24794431.001]
  • [Cites] Gut. 2002 Apr;50(4):451-9 [11889061.001]
  • [Cites] Am J Gastroenterol. 2011 Jun;106(6):1039-47 [21448147.001]
  • [Cites] J Gastroenterol. 2015 Apr;50(4):414-23 [25129514.001]
  • [Cites] Transl Res. 2015 Jul;166(1):28-40 [25701368.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] Neurogastroenterol Motil. 2010 Jul;22(7):746-51, e219 [20456759.001]
  • [Cites] Dig Dis Sci. 2014 Jan;59(1):89-97 [24096876.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2011 Aug;301(2):G203-9 [21617116.001]
  • [Cites] Nat Med. 2009 Jun;15(6):674-81 [19448635.001]
  • [Cites] Cytoskeleton (Hoboken). 2011 Dec;68(12):653-60 [22083950.001]
  • [Cites] Gut. 2013 Dec;62(12):1684-91 [23355549.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):4017-27 [19509166.001]
  • [Cites] Gastroenterology. 2014 May;146(5):1266-77.e1-9 [24486052.001]
  • [Cites] J Physiol Pharmacol. 2013 Apr;64(2):193-9 [23756394.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):569-78 [11342767.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1259-68 [1551533.001]
  • [Cites] J Gastroenterol. 2011 May;46(5):629-38 [21373849.001]
  • [Cites] Clin Transl Sci. 2015 Dec;8(6):841-7 [26211420.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1200-5 [8898633.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10 (19):6703-9 [15475461.001]
  • [Cites] Carcinogenesis. 2002 Dec;23(12):2095-102 [12507933.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2012 Jul 15;303(2):G199-208 [22575221.001]
  • [Cites] Gut. 2009 Mar;58(3):317-22 [19211847.001]
  • [Cites] Am J Physiol Cell Physiol. 2011 Jun;300(6):C1422-9 [21307344.001]
  • [Cites] Mol Cell Endocrinol. 2014 Jan 25;382(1):150-8 [23994026.001]
  • [Cites] Obes Surg. 2005 Oct;15(9):1225-32 [16259876.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1221-5 [16570048.001]
  • [Cites] Clin Transl Gastroenterol. 2015 Oct 08;6:e115 [26448456.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):772-83 [16998510.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9 [10845877.001]
  • [Cites] Clin Gastroenterol Hepatol. 2016 Feb;14 (2):175-82.e1-3 [25956834.001]
  • [Cites] Transl Res. 2010 Sep;156(3):180-7 [20801415.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Dec;285(6):F1078-84 [13129853.001]
  • [Cites] J Cell Biol. 2011 Mar 21;192(6):907-17 [21422226.001]
  • [Cites] Cancer Lett. 2016 Jan 1;370(1):117-24 [26519754.001]
  • [Cites] PLoS One. 2015 Oct 27;10(10):e0141410 [26506614.001]
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):329-41 [15970443.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2013 Apr 1;304(7):G662-72 [23370675.001]
  • [Cites] Gut. 2014 Jun;63(6):871-80 [23853213.001]
  • [Cites] Gut. 2006 Nov;55(11):1538-44 [16785284.001]
  • [Cites] Gut. 2010 Feb;59(2):164-9 [19880965.001]
  • [Cites] Inflamm Bowel Dis. 2006 Feb;12(2):100-5 [16432373.001]
  • [Cites] Ann N Y Acad Sci. 2012 Oct;1271:37-43 [23050962.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1930-5 [11344187.001]
  • [Cites] Gut. 2014 Feb;63(2):220-9 [23408348.001]
  • [Cites] Clin Gastroenterol Hepatol. 2014 Feb;12(2):229-238.e3 [23954649.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2014 Apr 15;306(8):G641-9 [24578343.001]
  • [Cites] Cytokine Growth Factor Rev. 2016 Oct;31:37-48 [27079372.001]
  • [Cites] Scand J Gastroenterol. 2010 Mar;45(3):282-91 [20001645.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2010 Dec;24(6):873-82 [21126700.001]
  • [Cites] Nat Cell Biol. 2010 May;12(5):468-76 [20418870.001]
  • [Cites] Nat Med. 2012 Mar 06;18(3):363-74 [22395709.001]
  • [Cites] Scand J Gastroenterol. 2006 Aug;41(8):887-91 [16803686.001]
  • [Cites] Med Sci Monit. 2009 May;15(5):CR203-210 [19396034.001]
  • [Cites] Gastroenterology. 2010 Jul;139(1):194-203.e1 [20303354.001]
  • [Cites] Curr Opin Gastroenterol. 2009 Jul;25(4):342-51 [19417644.001]
  • [Cites] Surg Obes Relat Dis. 2009 Sep-Oct;5(5):524-8 [19560978.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):154-65 [17241868.001]
  • [Cites] Nat Rev Immunol. 2008 Dec;8(12):923-34 [19029988.001]
  • [Cites] Tissue Barriers. 2013 Dec 1;1(5):e27463 [24790804.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2788-803 [17974918.001]
  • [Cites] Ann N Y Acad Sci. 2013 Oct;1300:296-314 [24117650.001]
  • [Cites] Clin Gastroenterol Hepatol. 2015 Dec;13(13):2265-72 [25737442.001]
  • [Cites] Gastroenterol Clin North Am. 2014 Mar;43(1):161-73 [24503366.001]
  • [Cites] Br J Surg. 2010 Jul;97(7):1020-7 [20632267.001]
  • [Cites] Gastroenterol Clin North Am. 2014 Mar;43(1):121-33 [24503363.001]
  • [Cites] Nature. 2003 Jun 12;423(6941):762-9 [12802337.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G211-8 [18556417.001]
  • [Cites] Br J Surg. 2014 May;101(6):643-52 [24664553.001]
  • [Cites] Gut. 2011 Dec;60(12):1635-43 [21672941.001]
  • [Cites] Biochem J. 2010 Aug 1;429(3):419-33 [20626351.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1131-9 [15271650.001]
  • [Cites] Gastroenterology. 2010 Oct;139(4):1115-27 [20727892.001]
  • [Cites] Cold Spring Harb Perspect Biol. 2009 Aug;1(2):a002584 [20066090.001]
  • [Cites] J Gastroenterol. 2011 Jul;46(7):883-93 [21590343.001]
  • [Cites] Gastroenterol Clin North Am. 2015 Jun;44(2):391-413 [26021201.001]
  • [Cites] PLoS One. 2012;7(12):e52272 [23284964.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):672-82 [12612906.001]
  • [Cites] Gut. 2003 Jul;52(7):942-6 [12801948.001]
  • [Cites] Clin Gastroenterol Hepatol. 2013 Apr;11(4):373-381.e1 [23220167.001]
  • [Cites] Clin Exp Gastroenterol. 2012;5:103-7 [22767997.001]
  • [Cites] Clin Gastroenterol Hepatol. 2015 Dec;13(13):2241-55.e1-4; quiz e179 [26188139.001]
  • [Cites] Curr Opin Gastroenterol. 2010 Jul;26(4):367-78 [20571388.001]
  • [Cites] Gut. 1999 May;44(5):598-602 [10205192.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2015 Jun 1;308(11):G904-23 [25882613.001]
  • [Cites] Nat Rev Cancer. 2015 Aug;15(8):484-98 [26205341.001]
  • [Cites] Gastroenterol Clin North Am. 2015 Jun;44(2):249-64 [26021193.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1431-3 [10688782.001]
  • [Cites] J Pathol. 2005 Nov;207(3):269-76 [16177953.001]
  • [Cites] J Gastroenterol. 2014 Jul;49(7):1121-34 [23955118.001]
  • [Cites] J Physiol Pharmacol. 2008 Sep;59(3):525-42 [18953095.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Jul;5(7):383-92 [18542113.001]
  • [Cites] Semin Cancer Biol. 2014 Apr;25:69-77 [24406209.001]
  • [Cites] J Transl Med. 2016 Jan 29;14 :30 [26822225.001]
  • [Cites] J Clin Biochem Nutr. 2007 Jan;40(1):13-23 [18437209.001]
  • [Cites] J Gastroenterol. 2005 Aug;40(8):781-90 [16143882.001]
  • [Cites] J Clin Gastroenterol. 2012 Feb;46(2):93-114 [22227731.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2010 May;298(5):G571-81 [20299604.001]
  • [Cites] Gut. 2014 Jan;63(1):191-202 [24092861.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):358-70; discussion 370-1 [8813264.001]
  • [Cites] Gastroenterol Clin North Am. 2010 Sep;39(3):393-418 [20951909.001]
  • [Cites] J Urol. 2001 Dec;166(6):2472-83 [11696814.001]
  • (PMID = 27441783.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA156733; United States / NCI NIH HHS / CA / U54 CA156735
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / Anti-Inflammatory Agents; 0 / IL4 protein, human; 0 / Immunologic Factors; 0 / TRPV Cation Channels; 0 / TRPV1 protein, human; 207137-56-2 / Interleukin-4
  • [Keywords] NOTNLM ; Barrett's esophagus / adiponectin / gastroesophageal reflux disease / interleukin 4 / stromal cells
  •  go-up   go-down


6. Tanwar PS, Kaneko-Tarui T, Zhang L, Tanaka Y, Crum CP, Teixeira JM: Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1. PLoS Genet; 2012;8(8):e1002906
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
  • Germline mutations of the Liver Kinase b1 (LKB1/STK11) tumor suppressor gene have been linked to Peutz-Jeghers Syndrome (PJS), an autosomal-dominant, cancer-prone disorder in which patients develop neoplasms in several organs, including the oviduct, ovary, and cervix.
  • Because similar changes in the stromal population are also observed in human oviductal/ovarian adenoma and endometrial adenocarcinoma patients, we predict that dysregulated mTORC1 activity by upstream mechanisms similar to those described in these model systems contributes to the pathogenesis of these human diseases.

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Science. 2004 Mar 12;303(5664):1684-6 [15017003.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3112-24 [15060135.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1533-8 [15231735.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] J Exp Zool. 1976 Jun;196(3):361-70 [932664.001]
  • [Cites] Gastroenterology. 1985 Apr;88(4):1060-4 [3972226.001]
  • [Cites] Am J Pathol. 1986 Sep;124(3):384-91 [2945438.001]
  • [Cites] Differentiation. 1986;32(1):49-58 [3536646.001]
  • [Cites] Cancer. 1988 Jul 1;62(1):142-9 [3383111.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Gynecol Oncol. 1994 May;53(2):256-64 [8188091.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1205-12 [7977943.001]
  • [Cites] Development. 1995 Dec;121(12):4057-65 [8575306.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Dev Biol. 2005 Dec 1;288(1):276-83 [16256976.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3209-15 [16707622.001]
  • [Cites] BJOG. 2006 Aug;113(8):902-8 [16753046.001]
  • [Cites] Int J Gynecol Pathol. 2006 Oct;25(4):361-5 [16990713.001]
  • [Cites] Genesis. 2007 Feb;45(2):101-6 [17245776.001]
  • [Cites] Dev Biol. 2007 Jul 15;307(2):227-36 [17532316.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1351-60 [17521700.001]
  • [Cites] Oncogene. 2007 Dec 13;26(57):7825-32 [17599048.001]
  • [Cites] J Pathol. 2008 Jan;214(2):199-210 [18161745.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):759-66 [18245476.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2414-25 [18227155.001]
  • [Cites] Nat Genet. 2008 Apr;40(4):455-9 [18311138.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2543-50 [18451215.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):446-57 [18058806.001]
  • [Cites] Mol Endocrinol. 2008 Oct;22(10):2336-52 [18687735.001]
  • [Cites] Endocrinology. 2008 Dec;149(12):6207-12 [18703631.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):6908-19 [19029933.001]
  • [Cites] Int J Mol Med. 2009 Feb;23(2):173-80 [19148540.001]
  • [Cites] PLoS One. 2009;4(4):e5137 [19340305.001]
  • [Cites] Mol Reprod Dev. 2009 Jul;76(7):678-88 [19197916.001]
  • [Cites] Arch Gynecol Obstet. 2009 Sep;280(3):445-8 [19130067.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6171-8 [19622772.001]
  • [Cites] Biol Reprod. 2009 Sep;81(3):545-52 [19403928.001]
  • [Cites] Hum Mol Genet. 2009 Nov 15;18(22):4428-41 [19692352.001]
  • [Cites] Int J Gynecol Cancer. 2009 Dec;19(9):1591-4 [19955943.001]
  • [Cites] Hum Mol Genet. 2010 Feb 1;19(3):397-410 [19843540.001]
  • [Cites] Cold Spring Harb Perspect Biol. 2009 Jul;1(1):a000513 [20066074.001]
  • [Cites] Dis Model Mech. 2010 Mar-Apr;3(3-4):181-93 [20142330.001]
  • [Cites] Gynecol Oncol. 2010 Apr;117(1):103-8 [20102778.001]
  • [Cites] Nat Rev Cancer. 2010 Jun;10(6):415-24 [20495575.001]
  • [Cites] Front Biosci (Elite Ed). 2010;2:882-905 [20515761.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E936-46 [20858757.001]
  • [Cites] J Biol Chem. 2011 Jan 7;286(1):341-53 [20974850.001]
  • [Cites] Cancer Res. 2011 Mar 1;71(5):1584-96 [21363919.001]
  • [Cites] Hum Mol Genet. 2011 Apr 1;20(7):1290-305 [21212099.001]
  • [Cites] PLoS One. 2011;6(6):e20715 [21695255.001]
  • [Cites] Gynecol Oncol. 2011 Aug;122(2):424-9 [21570712.001]
  • [Cites] J Mol Cell Biol. 2011 Dec;3(6):330-40 [21926085.001]
  • [Cites] Endocrinology. 2012 Jan;153(1):404-16 [22128018.001]
  • [Cites] Mod Pathol. 2012 Feb;25(2):197-211 [22080063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):204-11 [11410867.001]
  • [Cites] Dev Biol. 2001 Dec 1;240(1):194-211 [11784056.001]
  • [Cites] Genesis. 2002 Feb;32(2):148-9 [11857804.001]
  • [Cites] Hum Mol Genet. 2002 Mar 1;11(5):525-34 [11875047.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):162-7 [12226664.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):408-10 [12368913.001]
  • [Cites] Pathol Int. 2003 Feb;53(2):111-4 [12588440.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):471-6 [14614311.001]
  • [Cites] Nat Rev Genet. 2003 Dec;4(12):969-80 [14631357.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):18-24 [14729328.001]
  • (PMID = 22916036.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD052701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multiprotein Complexes; 0 / Proteins; 0 / Tumor Suppressor Proteins; 0 / mechanistic target of rapamycin complex 1; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.1.- / Stk11 protein, mouse; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / Pten protein, mouse; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC3420942
  •  go-up   go-down


7. Hashimoto M, Koide K, Arita M, Kawaguchi K, Tokunaga M, Mikuriya Y, Iwamoto T: Acute acalculous cholecystitis due to breast cancer metastasis to the cystic duct. Surg Case Rep; 2016 Dec;2(1):111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Acute acalculous cholecystitis (AAC) is a relatively rare disorder of the gallbladder.
  • Laboratory tests showed a severe inflammatory reaction and mild liver function abnormalities.
  • We performed an emergency laparoscopic cholecystectomy, and histopathological examination revealed a poorly differentiated adenocarcinoma in the cystic duct.
  • The final pathological diagnosis was acute cholecystitis due to breast cancer metastasis to the cystic duct.
  • CONCLUSION: Although AAC secondary to metastatic breast cancer is rare, it should be included in the differential diagnosis for abdominal pain in patients with a previous history of breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1983 Aug;146(2):269-73 [6881454.001]
  • [Cites] Breast Cancer. 2005;12(3):161-5 [16110285.001]
  • [Cites] Breast Cancer. 2016 Sep 15;:null [27628678.001]
  • [Cites] Clin Transl Oncol. 2015 Nov;17(11):895-902 [26081286.001]
  • [Cites] J Surg Oncol. 1986 Apr;31(4):240-2 [3724179.001]
  • [Cites] Oncology. 2013;85(2):100-10 [23867253.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3445-8 [19661371.001]
  • [Cites] N Engl J Med. 2016 Jul 21;375(3):209-19 [27264120.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1144-51 [7738620.001]
  • [Cites] Am Surg. 1998 May;64(5):471-5 [9585788.001]
  • [Cites] N Engl J Med. 2002 Oct 17;347(16):1233-41 [12393820.001]
  • [Cites] Am J Surg. 1981 Feb;141(2):194-8 [7457736.001]
  • [Cites] Case Rep Oncol. 2010 Jan 29;3(1):30-34 [20740155.001]
  • [Cites] Endoscopy. 2002 Dec;34(12 ):959-65 [12471539.001]
  • [Cites] Breast Cancer Res Treat. 2005 Dec;94(3):273-8 [16261405.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):433-7 [2322038.001]
  • [Cites] Oncology. 2006;71(5-6):361-8 [17785993.001]
  • [Cites] J Gastroenterol. 2001 Sep;36(9):619-22 [11578066.001]
  • [Cites] World J Surg Oncol. 2007 Sep 11;5:101 [17848197.001]
  • [Cites] Dig Dis Sci. 1991 Apr;36(4):520-3 [2007370.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14 (1):98-113 [17252303.001]
  • [Cites] Acta Anaesthesiol Scand. 2004 Sep;48(8):986-91 [15315616.001]
  • [Cites] Int J Gastrointest Cancer. 2001;30(3):147-60 [12540027.001]
  • [Cites] S Afr J Surg. 1999 Nov;37(4):99-104 [10701340.001]
  • [Cites] Curr Gastroenterol Rep. 2003 Aug;5(4):302-9 [12864960.001]
  • [Cites] Digestion. 2014;90(2):75-80 [25196261.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):512-9 [16996341.001]
  • (PMID = 27730536.001).
  • [ISSN] 2198-7793
  • [Journal-full-title] Surgical case reports
  • [ISO-abbreviation] Surg Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Acute cholecystitis / Biliary metastasis / Breast cancer / Late recurrence
  •  go-up   go-down


8. Ogata Y, Matono K, Tsuda H, Ushijima M, Uchida S, Akagi Y, Shirouzu K: Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer. PLoS One; 2015;10(3):e0120064
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.
  • This open label, non- blinded randomized phase II study compared the efficacy of hepatic arterial infusion (HAI) with 5-fluorouracil,with or without antineoplastons as a postoperative therapy for colorectal metastasis to the liver.
  • METHODS: Sixty-five patients with histologically confirmed metastatic colon adenocarcinoma in liver, who had undergone hepatectomy, and/or thermal ablation for liver metastases were enrolled between 1998- 2004 in Kurume University Hospital.
  • Patients were randomly assigned to receive systemic antineoplastons (A10-I infusion followed by per-oral AS2-1) plus HAI (AN arm) or HAI alone (control arm) based on the number of metastases and presence/ absence of extra-hepatic metastasis at the time of surgery.
  • No serious toxicity, including bone marrow suppression, liver or renal dysfunction, were found in the AN arm.
  • INTERPRETATION: Antineoplastons (A10 Injection and AS2-1) might be useful as adjunctive therapy in addition to HAI after hepatectomy in colorectal metastases to the liver.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / drug therapy. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Glutamine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):643-50 [11034240.001]
  • [Cites] Physiol Chem Phys. 1976;8(3):275-9 [1013179.001]
  • [Cites] Cancer Res. 1978 Nov;38(11 Pt 1):3784-92 [151583.001]
  • [Cites] Jpn J Cancer Res. 1992 May;83(5):527-31 [1377669.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2288-95 [8486788.001]
  • [Cites] J Invest Dermatol. 1994 Sep;103(3):335-40 [8077698.001]
  • [Cites] Kurume Med J. 1995;42(4):241-9 [8667595.001]
  • [Cites] Kurume Med J. 1996;43(2):137-47 [8755117.001]
  • [Cites] Surgery. 1998 Sep;124(3):541-50 [9736908.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):501-8 [10024683.001]
  • [Cites] Mayo Clin Proc. 1999 Feb;74(2):137-45 [10069350.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):389-95 [15706406.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):734-5 [15716576.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD003770 [17054184.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4976-82 [17075115.001]
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):995-1001 [17465233.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4575-80 [17925551.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5649-54 [18065736.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):125-35 [18156932.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4906-11 [18794541.001]
  • [Cites] Drugs R D. 2011 Sep 1;11(3):227-49 [21902286.001]
  • [Cites] J Clin Oncol. 2012 Sep 20;30(27):3361-7 [22915658.001]
  • [Cites] Future Oncol. 2013 Feb;9(2):255-69 [23414475.001]
  • [Cites] Oncol Rep. 2014 Jan;31(1):19-26 [24213840.001]
  • [Cites] PLoS One. 2015;10(3):e0120064 [25790229.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2039-48 [10615075.001]
  • (PMID = 25790229.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] JPRN/ UMIN000012099
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Benzeneacetamides; 0 / Drug Combinations; 0 / Phenylacetates; 0 / Piperidones; 0RH81L854J / Glutamine; 104624-98-8 / antineoplaston AS 2-1; 91531-30-5 / antineoplaston A10; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4366171
  •  go-up   go-down


9. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, Assanah EO, Davies R, Espat NJ, Junghans RP: Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. Clin Cancer Res; 2015 Jul 15;21(14):3149-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.
  • Successful adaptation of CAR-T technology for CEA-expressing adenocarcinoma liver metastases, a major cause of death in patients with gastrointestinal cancers, has yet to be achieved.
  • We sought to test intrahepatic delivery of anti-CEA CAR-T through percutaneous hepatic artery infusions (HAIs).
  • EXPERIMENTAL DESIGN: We conducted a phase I trial to test HAI of CAR-T in patients with CEA(+) liver metastases.
  • RESULTS: Four patients had more than 10 liver metastases, and patients received a mean of 2.5 lines of conventional systemic therapy before enrollment.
  • Biopsies demonstrated an increase in liver metastasis necrosis or fibrosis in 4 of 6 patients.
  • Further clinical testing of CAR-T HAIs for liver metastases is warranted.
  • [MeSH-major] Adenocarcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Immunotherapy / methods. Liver Neoplasms / therapy. Receptors, Antigen, T-Cell / administration & dosage. T-Lymphocytes / transplantation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2015 American Association for Cancer Research.
  • [Cites] J Clin Immunol. 1990 May;10(3):167-74 [2164039.001]
  • [Cites] J Immunol. 2011 Aug 1;187(3):1150-6 [21697460.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2391-6 [1657353.001]
  • [Cites] N Engl J Med. 2011 Aug 25;365(8):725-33 [21830940.001]
  • [Cites] Trends Biotechnol. 2011 Nov;29(11):550-7 [21663987.001]
  • [Cites] N Engl J Med. 2012 Jun 28;366(26):2443-54 [22658127.001]
  • [Cites] N Engl J Med. 2012 Jun 28;366(26):2455-65 [22658128.001]
  • [Cites] Ann Surg Oncol. 2013 Mar;20(3):946-55 [23010736.001]
  • [Cites] N Engl J Med. 2013 Apr 18;368(16):1509-18 [23527958.001]
  • [Cites] Cancer Res. 2013 Nov 15;73(22):6584-96 [24121495.001]
  • [Cites] Prostate. 2014 Feb;74(3):286-96 [24174378.001]
  • [Cites] Nat Mater. 2014 Feb;13(2):106-9 [24452344.001]
  • [Cites] PLoS One. 2014;9(2):e89357 [24586714.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2310-7 [18521684.001]
  • [Cites] Cancer Gene Ther. 2014 Nov;21(11):457-62 [25277132.001]
  • [Cites] Cancer Immunol Res. 2014 Jun;2(6):530-7 [24894090.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5233-9 [18809613.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8112-22 [19088026.001]
  • [Cites] Curr Opin Immunol. 2009 Apr;21(2):215-23 [19327974.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3465-71 [19470932.001]
  • [Cites] Ann Surg Oncol. 2009 Sep;16(9):2524-30 [19568816.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7412-20 [19934295.001]
  • [Cites] Clin Cancer Res. 2010 May 15;16(10):2769-80 [20460472.001]
  • [Cites] Br J Surg. 2000 Jan;87(1):43-8 [10606909.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):802-7 [11022927.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):859-60 [11252319.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Oct;17(5):545-52 [12470424.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):1009-17 [14707074.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):230-5 [15210779.001]
  • [Cites] Nature. 1967 Aug 12;215(5102):744-5 [6059543.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2624-9 [2986820.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2865-75 [2993418.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3478-85 [7683969.001]
  • [Cites] Eur J Cancer. 1994;30A(1):103-5 [8142149.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):968-75 [10071291.001]
  • [Cites] Hepatology. 2005 Aug;42(2):293-300 [16025518.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1325-31 [16269610.001]
  • [Cites] BMC Cancer. 2007;7:2 [17201906.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5649-54 [18065736.001]
  • [Cites] Hum Gene Ther. 2007 Dec;18(12):1253-60 [18052719.001]
  • [Cites] J Virol Methods. 2008 Mar;148(1-2):253-9 [18249448.001]
  • [Cites] HPB (Oxford). 2010 Dec;12(10):674-83 [21083792.001]
  • [Cites] Mol Ther. 2011 Mar;19(3):620-6 [21157437.001]
  • [Cites] Eur J Cancer. 1990;26(10):1106-7 [2148889.001]
  • (PMID = 25850950.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA160662; United States / NCI NIH HHS / CA / 1K08CA160662-01A1
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Other-IDs] NLM/ NIHMS679134; NLM/ PMC4506253
  •  go-up   go-down


10. Gandhi K, Parikh P, Aronow WS, Desai H, Amin H, Sharma M, Rubinstein A: A case of explosive progression of hepatocellular carcinoma in a patient with common variable immunodeficiency (CVID). J Gastrointest Cancer; 2010 Dec;41(4):281-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: While it is well known that patients with common variable immunodeficiency (CVID) are predisposed to various malignancies, primarily non-Hodgkin's lymphoma and gastric carcinomas, to our knowledge no cases of hepatocellular carcinoma have been reported in the absence of preexisting liver disease.
  • The patient was on prophylactic intravenous gammaglobulin and had received several years earlier a course of rituximab for an autoimmune disorder.
  • CONCLUSIONS: Although patients with CVID are predisposed to malignancies such as lymphoma and adenocarcinoma of the stomach, rapidly progressive hepatocellular carcinoma in the absence of any preexisting liver disease has not been described.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Common Variable Immunodeficiency / complications. Liver Neoplasms / etiology

  • Genetic Alliance. consumer health - Common Variable Immunodeficiency.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Arch Allergy Immunol. 2009;150(4):311-24 [19571563.001]
  • [Cites] J Clin Immunol. 2007 May;27(3):308-16 [17510807.001]
  • [Cites] Clin Exp Med. 2004 Apr;3(4):211-7 [15103511.001]
  • [Cites] J Intern Med. 1996 Aug;240(2):99-102 [8810936.001]
  • [Cites] Hepatol Res. 2008 Apr;38(4):415-20 [18021227.001]
  • [Cites] Clin Immunol. 1999 Dec;93(3):190-7 [10600329.001]
  • [Cites] Clin Immunol. 1999 Jul;92(1):34-48 [10413651.001]
  • [Cites] Q J Med. 1993 Jan;86(1):31-42 [8438047.001]
  • [Cites] Ann Allergy Asthma Immunol. 2005 May;94(5 Suppl 1):S1-63 [15945566.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):489-502 [18692715.001]
  • [Cites] Eur J Pediatr. 1996 Jul;155(7):532-4 [8831072.001]
  • [Cites] Curr Opin Genet Dev. 2007 Jun;17(3):201-12 [17467261.001]
  • [Cites] Lancet. 1985 Feb 2;1(8423):263-6 [2857327.001]
  • [Cites] Clin Exp Immunol. 2002 Dec;130(3):495-500 [12452841.001]
  • [Cites] Am J Hematol. 2002 Mar;69(3):171-8 [11891803.001]
  • [Cites] J Clin Immunol. 1987 Jul;7(4):294-9 [3611296.001]
  • (PMID = 20473587.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors
  •  go-up   go-down






Advertisement